1. Introduction {#sec1-cancers-11-00900}
===============

The GLOBOCAN 2018 data estimates that 18.1 million new cancer cases and 9.6 million cancer deaths occur worldwide. Pancreatic cancer (PC) accounts for 2.5% of the new cases and 4.5% of the overall death \[[@B1-cancers-11-00900]\]. PC is the 12th most prevalent malignancy throughout the globe with 338,000 new cases recognised in 2012, and the five-year average prevalence rate was found to be 4.1 in 100,000 people throughout the world \[[@B2-cancers-11-00900]\]. It has one of the lowest survival rates among the predominant tumours with a single digit five-year survival rate (2--9%) \[[@B3-cancers-11-00900]\]. According to GLOBOCAN 2015 data, 1000 cases of PC are diagnosed daily \[[@B4-cancers-11-00900]\], and 985 deaths \[[@B5-cancers-11-00900]\] occur worldwide daily. With regards to India, cancer is one of the leading causing of death behind cardiovascular disease \[[@B6-cancers-11-00900]\]. According to a study, the estimated annual PC burden in India in 2001 was 14,230 cases.

The mainstay of non-metastatic PC treatment is surgery \[[@B7-cancers-11-00900]\]. Surgery is the most useful local treatment, but despite this, survival rates are modest primarily due to problems with distant and local recurrence issues. Therapeutic agents that are utilised as adjuvant or neo-adjuvant therapies are radiotherapy and systemic therapies (chemotherapies, targeted therapies). These include 5-Fluorouracil (5-FU) \[[@B8-cancers-11-00900]\], 5-FU-based combinations like doxorubicin and mitomycin (FAM) \[[@B9-cancers-11-00900]\], docetaxel \[[@B10-cancers-11-00900]\], irinotecan \[[@B11-cancers-11-00900]\], Gemcitabine (GEM) \[[@B12-cancers-11-00900]\], irinotecan and oxaliplatin (FOLFIRINOX), GEM-based combination therapies such as 5-FU \[[@B13-cancers-11-00900]\], capecitabine \[[@B14-cancers-11-00900]\], S-1 \[[@B15-cancers-11-00900]\], cisplatin \[[@B16-cancers-11-00900]\], irinotecan \[[@B17-cancers-11-00900]\], cisplatin, epirubicin and 5-FU (PEFG) \[[@B18-cancers-11-00900]\], oxaliplatin \[[@B19-cancers-11-00900]\], erlotinib \[[@B20-cancers-11-00900]\] and nab-paclitaxel \[[@B21-cancers-11-00900]\]. Other management options include nanocarriers \[[@B22-cancers-11-00900]\], palliative care \[[@B23-cancers-11-00900]\], immunotherapy \[[@B24-cancers-11-00900]\].

MicroRNAs (miRNAs) are short (20--25 nucleotide) non-coding sequences increasingly recognised as molecular markers for the early detection of cancer and prognostication of clinical outcomes \[[@B25-cancers-11-00900],[@B26-cancers-11-00900],[@B27-cancers-11-00900],[@B28-cancers-11-00900],[@B29-cancers-11-00900]\]. miRNAs regulate cell proliferating genes such as c-Myc and E2F1 thereby playing a critical role in cancer progression \[[@B30-cancers-11-00900],[@B31-cancers-11-00900]\]. Differential expression of apoptosis-regulating genes was found to be associated with the 5-FU and GEM resistance in PC cell lines \[[@B32-cancers-11-00900]\]. A tumour suppressing the role of miRNA was illustrated by the miR-96 miRNA which acts by suppressing KRAS gene in PC both in vitro and in vivo \[[@B33-cancers-11-00900]\]. miRNA profiling by real-time PCR in PC cell lines and patient PC tissue samples revealed a range of 95 miRNAs that were altered \[[@B34-cancers-11-00900]\]. Li Y et al. (2009) demonstrated that miRNA 200 and let-7a lead to the reversal of the epithelial-mesenchymal transition (EMT) in GEM-resistant pancreatic cancer cells \[[@B35-cancers-11-00900]\]. A study by Zhu et al. observed that miRNA 27a and 451 were upregulated in multidrug-resistant cell lines (A2780DX5 and KB-V1) along with the overexpression of P-glycoprotein (P-gp) \[[@B36-cancers-11-00900]\]. In the case of resistance due to the upregulation of miRNA-451, the transfection of miRNA-451 in doxorubicin-resistant MCF-7 cell lines increased the sensitivity to doxorubicin significantly \[[@B37-cancers-11-00900]\].

Drug resistance is classified as intrinsic if it is present before treatment and acquired resistance if it develops while on treatment. There are several reviews involving miRNA and chemotherapy resistance \[[@B38-cancers-11-00900],[@B39-cancers-11-00900],[@B40-cancers-11-00900]\]. Ali S et al. (2010) induced GEM sensitivity in PC cells through modulation of miR-200 and 21 by curcumin \[[@B41-cancers-11-00900]\]. Reversal of EMT was achieved through natural agents (3,3′-diindolylmethane (DIM) or isoflavone) by upregulating miR-200 and let-7a in GEM-resistant PC cell lines \[[@B35-cancers-11-00900]\]. The Notch signalling pathway is linked with the acquisition of EMT in GEM-resistant PC cell lines \[[@B42-cancers-11-00900]\]. CD44-positive cancer stem cells (CSCs) were recently noted to be responsible for GEM-resistance in PC \[[@B43-cancers-11-00900]\].

An increasing number of publications in recent years correlate miRNA expression in PC with resistance or sensitivity towards chemotherapeutic targets. Currently, the data on the correlations between PC chemoresistance/sensitivity and miRNA expression has not yielded clinically relevant solutions, in the form of prognostic biomarkers, despite the ongoing research in this field. A systematic review and meta-analysis approach allows us to collate the data across all published studies in the field and possibly highlight the associated miRNA, which may have clinical relevance in directing decisions regarding chemotherapy in PC patients \[[@B44-cancers-11-00900],[@B45-cancers-11-00900],[@B46-cancers-11-00900],[@B47-cancers-11-00900]\]. Our study would help prospective scholars and clinicians by cataloguing miRNA alterations associated with chemotherapeutic response in this deadly disease. Future studies can then define their utility as predictors of chemotherapy response.

Our study aims to elucidate the relationship between miRNA expression and chemotherapeutic resistance or susceptibility in PC through a systematic review and meta-analysis of extant literature.

2. Methods {#sec2-cancers-11-00900}
==========

2.1. Search Strategy and Study Selection {#sec2dot1-cancers-11-00900}
----------------------------------------

Current studies in PC involving miRNA related drug resistance were identified through PubMed and Science Direct using the search terms; "microRNAs or miRNAs" AND "drug resistance" AND "PC" in combination. Four authors of this study (RJ, MRM, RR, and RS) independently performed a literature search systematically using the databases mentioned above ([Supplementary Table S1](#app1-cancers-11-00900){ref-type="app"}). The study period was January 2008 to December 2018, inclusive. The search was limited to 10 years to make the information obtained relevant and contemporary. No language restriction was applied. The cross-references from the selected studies were searched for additional articles. Corresponding authors were contacted when the relevant information was not available in the publication. Discrepancies were resolved through discussion and consensus with a third reviewer.

2.2. Selection Criteria {#sec2dot2-cancers-11-00900}
-----------------------

The current study follows the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines \[[@B48-cancers-11-00900]\]. The selection of studies was made based on the following inclusion and exclusion criteria.

2.3. Inclusion Criteria {#sec2dot3-cancers-11-00900}
-----------------------

Studies involving miRNAs expression and PC.Studies involving clinical patient data or preclinical data.Studies focusing on the resistance to some form of chemotherapy.Studies that reported the miRNA profiling platforms.Articles using in vitro assays to analyse the expression of miRNAs or gene related studies.

2.4. Exclusion Criteria {#sec2dot4-cancers-11-00900}
-----------------------

Studies published in non-English language and that do not involve drug resistance in PC were removed.Case reports, review articles, editorial, and studies with only in vitro or only PC patient samples data were excluded.

2.5. Data Extraction {#sec2dot5-cancers-11-00900}
--------------------

MS Office Excel worksheet was used to collect information about studies that were included for extraction. Prior PRISMA guidelines were used to design the data sheet content. Full text and corresponding [supplementary information](#app1-cancers-11-00900){ref-type="app"} of the following items were collected and recorded from the eligible studies; first author, year of publication, patient information, location of the study, ethnicity, gender, drug used, clinical stage, number of samples, lymph node metastasis, cell line(s) used, miRNA(s) involved, miRNA profiling platform, and drug pathways or genes associated.

2.6. Quality Assessment {#sec2dot6-cancers-11-00900}
-----------------------

The quality of eligible studies was assessed by two authors (RJ and MRM) critically according to the meta-analysis of observational studies in epidemiology (MOOSE) \[[@B49-cancers-11-00900]\] for epidemiological studies by the predefined checklist. The qualifying studies had all the criteria either mentioned in the study or later denoted by the corresponding author ([Supplementary Table S2](#app1-cancers-11-00900){ref-type="app"}).

2.7. Publication Bias {#sec2dot7-cancers-11-00900}
---------------------

Two authors (R.J. and M.M.R.) assessed the risk of bias through a few distinct methods \[[@B47-cancers-11-00900],[@B50-cancers-11-00900],[@B51-cancers-11-00900],[@B52-cancers-11-00900],[@B53-cancers-11-00900]\]. Egger's and Begg's bias indicator test was used to calculating publication bias along with an inverted funnel plot. Begg-Mazumdar bias indicator test was done to check the effect of publication and selection bias. Duval and Tweedie's trim and fill calculation was calculated additionally to compute the effect size.

2.8. Meta-Analysis {#sec2dot8-cancers-11-00900}
------------------

A meta-analysis was performed for the obtained HR values and 95% confidence interval (CI) from the articles and Kaplan-Meier curves of the eligible studies using comprehensive meta-analysis (CMA) software version 3.0. Random effects models were used for meta-analysis. Cochran's *Q* test and the *I*^2^ statistic \[[@B54-cancers-11-00900]\] were performed to assess the statistical heterogeneity. If *p*-value \> 0.05 heterogeneity was observed and the random effects model was performed. Forest plot was drawn to summarise the pooled HR estimate of the chemoresistance specific miRNAs.

3. Results {#sec3-cancers-11-00900}
==========

[Figure 1](#cancers-11-00900-f001){ref-type="fig"} explains our search selection and strategy in the form of a flowchart. The initial search resulted in 2671 studies from PubMed (*n* = 251) and Science Direct (*n* = 2420). After implementing the exclusion criteria, 169 articles were deemed relevant. After full-text screening and applying inclusion criteria, a total of 43 studies with miRNA expression related chemosensitivity or chemoresistance totalling 1963 individuals with PC was obtained for this study. The eligible articles were further reviewed (R.J., M.M.R.) and examined for data extraction (R.R. and R.S.). All the papers studied in our systematic review and meta-analysis were published in English. Out of the 43 studies, 23 were from China, seven were from the USA, seven were from Japan, five were from Germany, and one was from the Netherlands. Almost all studies (39 studies) used GEM as the primary drug for the treatment of PC. Both frozen and formalin fixed paraffin embedded (FFPE) tissue samples were used in the studies. [Table 1](#cancers-11-00900-t001){ref-type="table"} represents the descriptive characteristics of the included studies.

The most common assays performed is represented in [Figure 2](#cancers-11-00900-f002){ref-type="fig"}. A total of 59 cell lines have been used in the 43 studies, and PANC-1,2, Capan-1,2, HPDE and BxPc3 were the most commonly used ones. miRNA-21 modulates biological functions of PC cells including their proliferation, invasion, and chemoresistance studies used the highest number of cell lines (*n* = 14) \[[@B94-cancers-11-00900]\].

In total, 48 miRNA have been studied in our systematic review; 23 of them were downregulated, and 25 were upregulated. In particular, nine upregulated miRNAs (15b, 17-5p, 21, 155, 181c, 203, 221, 320c and 1246) exhibited chemotherapeutic resistance and six upregulated miRNAs (21, 33a, 138-5p, 509-5p, 1207 and 1243) exhibited chemotherapeutic sensitivity. In contrast, nine downregulated miRNAs (7, 100, 124, 210, 200c, 205, 220b, 374b-5p and 497) exhibited chemotherapeutic resistance and nine downregulated miRNAs (101, 101-3p, 153, 203, 205-5p, 494, 506, 3656, let-7a) exhibited chemotherapeutic sensitivity. Four miRNA were differentially expressed. Overall, chemotherapeutic resistance (*n* = 18) and chemotherapeutic sensitivity (*n* = 15) were influenced by the miRNAs studied. The studies used GEM, lapatinib, capecitabine, 5-FU, a gamma-secretase inhibitor, Tarceva, radiation therapy, and AZD8055.

Treatment with GEM led to the downregulation of miRNA 210 via the ABCC5 pathway, miRNA 124 via the polypyrimidine tract binding protein (PTBP1) and pyruvate kinase pathway, miRNA 103 via the ribonucleotide reductase M1 (RRM1) pathway, miRNA 100 via the FGFR3 pathway, miRNA 497 via the FGFR signalling pathway and miRNA 7 and 2015 via the class III b-tubulin (TUBB3) pathway; causing a chemoresistance phenotype.

Treatment with GEM also led to the upregulation of miRNA 17-5p via the PTEN pathway, miRNA 221 via the EGFR1 and HER2 pathway, miRNA 203 via the activation of salt-inducible kinase (SLK1), miRNA 181c via the Hippo signalling pathway, miRNA 15b via the SMAD specific proteins pathway, miRNA 21 via the PTEN/Akt pathway, and VEGF, MMP-2 and MMP-9 proteins. Some studies noted upregulated miRNAs such as miRNA 221, 10a-5p and 21 no mechanistic pathways were identified. The upregulation of these miRNAs due to GEM treatment resulted in chemoresistance.

GEM treatment also led to the downregulation of miRNAs, causing an increase in chemosensitivity, such as miRNA 3656 via EMT, miRNA let-7a via the HMGA2 pathway, miRNA 205-5p via the activation of K-Ras, Caveolin-1 and Ki-67, miRNA 153 via the SNAIL pathway, miRNA 101 via DNA-PKcs, miRNA 506 via the activation of NF-κB and SPHK1, miRNA 494 via SIRT1, c-myc pathway, miRNA 203 via the ZEB-1 pathway. GEM treatment upregulated some miRNAs causing an increase in chemosensitivities such as miRNA 509-5p and 1243 both via the E-cadherin pathway, miRNA 33a via the Akt/B-catenin pathway and miRNA 21 via the FasL/Fas pathway.

5-FU is another drug that affects the regulation of miRNAs. Treatment with 5-FU led to the downregulation of miRNAs, thereby increasing chemoresistance, such as miRNA 200c and 200b both via directly targeting SUZ12, ROCK2. Treatment with 5-FU led to the upregulation of miRNA 1246 via the CCNG2 pathway, increasing chemoresistance. 5-FU also led to the downregulation of miRNA 494 via the SIRT1/c-myc pathway. Also, the upregulation of miRNA 138-5p via the vimentin resulted in chemosensitisation ([Figure 3](#cancers-11-00900-f003){ref-type="fig"}).

The miRNA and their drug targets based on the chemotherapeutic resistance and sensitivity is separated and listed out in [Table 2](#cancers-11-00900-t002){ref-type="table"} and [Table 3](#cancers-11-00900-t003){ref-type="table"} respectively.

4. Meta-Analysis {#sec4-cancers-11-00900}
================

Associations between miRNA expression and patient survival were analysed using meta-analysis. The thorough screening revealed that 30 out of 43 studies did not report the HR values and 95% CI. Consequently, 30 studies were omitted from our meta-analysis due to insufficient reportage of data on patient survival and miRNA expressions. Collectively, 1088 patients from 12 studies were included in our meta-analysis ([Figure 4](#cancers-11-00900-f004){ref-type="fig"}). A pooled HR value of 1.603; 95% CI 1.2--2.143; *p*-value = 0.001 was obtained from a meta-analysis. Subgroup analysis between miR-21 showed an HR value of 2.061; 95% CI 1.195--3.556 and *p*-value of 0.009. Heterogeneity (*I*^2^ value) was observed to be 83.833 ([Figure 5](#cancers-11-00900-f005){ref-type="fig"}).

PC patients with elevated expression of miR-10a-5p (HR = 2.878, 95% CI = 1.614--5.131), 17-5p (HR = 1.18, 95% CI = 0.979--1.414), 21 (HR = 1.71, 95% CI = 1.147--2.535), 21 (HR = 0.32, 95% CI = 0.166--0.6), 33a (HR = 1.08, 95% CI = 1.002--1.168), 153 (HR = 1.16, 95% CI = 0.43--3.16), 181c (HR = 2.03, 95% CI = 1.33--3.11), 497 (HR = 2.76, 95% CI = 1.159--6.579), 506 (HR = 1.88, 95% CI = 1.048--3.026), 744 (HR = 21.2, 95% CI = 3.17--436) and 3656 (HR = 2.32, 95% CI = 1.37--3.57) exhibited chemotherapeutic resistance and a poorer prognosis. The low expression of miRNA-374b-5p (HR = 0.3, 95% CI = 0.17--0.54) revealed chemotherapeutic sensitivity and a better prognosis.

[Figure 4](#cancers-11-00900-f004){ref-type="fig"} represents the forest plot of the primary meta-analysis of the pooled HR values along with the 95% CI from a pancreatic cancer patient, which are calculated using comprehensive meta-analysis (CMA) software (version 3.3.070, Biostat, Englewood, NJ, USA). The graphical representation of the right side of the plot is the HR, and 95% of the included studies and the red squares with the line represents the effect size of miRNA expressions. If the HR value is more than 1, it indicates the increased risk of the patient's survival and less than specifies the decreased risk of patient's survival. The size of the box indicates the weight of the study.

5. Publication Bias Indicators {#sec5-cancers-11-00900}
==============================

5.1. Classic Fail-Safe N {#sec5dot1-cancers-11-00900}
------------------------

This meta-analysis incorporates data from 12 studies, which yield a *z*-value of 6.26484 and the corresponding two-tailed *p*-value of 0.00000. The fail-safe N is 111. This means that we would need to locate and include 111 'null' studies in order for the combined two-tailed *p*-value to exceed 0.050. Stated in another way, there would need to be 5.7 missing studies for every observed study for the effect to be nullified.

5.2. Orwin Fail-Safe N {#sec5dot2-cancers-11-00900}
----------------------

Here, the hazard ratio in observed studies is 1.150, which did not fall between the mean hazard ratio in the missing studies, so we could therefore not calculate the Orwin fail-safe N.

5.3. Begg and Mazumdar Rank Correlation Test {#sec5dot3-cancers-11-00900}
--------------------------------------------

The Kendall′s tau b is 0.25758, with a one-tailed *p*-value of 1.16573 or a two-tailed *p*-value of 0.12186. This value compares the effect size and variance with the tau value and the value closes to 1 correlates to signify the publication bias.

5.4. Egger′s Test of the Intercept {#sec5dot4-cancers-11-00900}
----------------------------------

In this case the intercept (B0) is 1.77800, 95% CI (−0.02031--3.57630), with *t* = 2.20298, df = 10. The 1-tailed *p*-value is 0.02609, and the 2-tailed *p*-value is 0.05218.

5.5. Duval and Tweedie′s Trim and Fill Test {#sec5dot5-cancers-11-00900}
-------------------------------------------

Under the fixed effect model, the point estimate and 95% confidence interval for the combined studies are 1.15084 (1.07656, 1.23025). Using trim and fill, the imputed point estimate is 1.10505 (1.03516, 1.17967). Under the random effects model, the point estimate and 95% confidence interval for the combined studies are 1.60344 (1.19976, 2.14294). Using trim and fill, the imputed point estimate is 1.13206 (0.85429, 1.50016).

The hypothesis and heterogeneity testing are represented in [Table 4](#cancers-11-00900-t004){ref-type="table"}.

Funnel plot is represented in [Figure 6](#cancers-11-00900-f006){ref-type="fig"}, and funnel plot with observed and imputed studies in [Figure 7](#cancers-11-00900-f007){ref-type="fig"}, which represents the possible bias between the included studies. If the studies have no publication bias, then the points will fall on the central line, indicating the symmetry. Every study or cohort included in the forest plot is represented as a point on the funnel plot.

6. Discussion {#sec6-cancers-11-00900}
=============

Emerging studies have revealed that specific miRNA expression in PC is related to chemotherapeutic sensitivity/resistance and regulation of molecular signalling pathways. Therefore, a systematic review and meta-analysis to catalogue the miRNA expression patterns and decipher the relationships and regulation of oncogenic signalling pathways to outcomes would help in the prediction of chemotherapy response and triaging of future clinical therapeutic strategies in PC.

We conducted this systematic review of published studies on miRNA expressions to inventory the full range of chemotherapeutic resistance and sensitivity in PC. To our knowledge, this is the first systematic review and meta-analysis describing the role of miRNA expression in chemotherapeutic resistance and sensitivity as well as molecular signalling pathways in PC. A total of 43 studies with 1963 patients were evaluated with 2207 PC tissue samples analysed. Also, 162 blood samples from the PC patients were examined in our study.

We found that distinct miRNAs were upregulated or downregulated in PC cell lines and tissues. In turn, they targeted specific molecular signalling pathways to mediate sensitivity or resistance to chemotherapeutic drugs in PC. Of the eight chemotherapeutic drugs studied individually and in combinations, GEM was the most studied followed by 5-FU.

In a study on lung cancer cells, miR-17-5p downregulation was associated with an increased expression of beclin 1 gene, which is an autophagy modulator in the survival pathway \[[@B96-cancers-11-00900]\]. Furthermore, this miRNA belongs to the miR-17-92 cluster and is upregulated in PC, where it is linked to pancreatic carcinogenesis \[[@B97-cancers-11-00900],[@B98-cancers-11-00900]\]. Downregulation of miRNA 7 and 205 resulted in chemoresistance in PC, and a possible target is TUBB3, as noted in another study \[[@B99-cancers-11-00900],[@B100-cancers-11-00900]\].

Our meta-analysis showed a non-significant pooled effect size, suggesting that drug-resistance specific miRNAs may not necessarily be good predictors of patient survival. However, it is essential to note that we have used only nine clinical studies in our meta-analysis due to a general lack of studies reporting clinical outcomes via HR and 95% CI values. From the data on publication bias, we concluded that several factors might be responsible for high heterogeneity between the data, such as study strategy, inadequate information and sample size \[[@B101-cancers-11-00900]\]. The publication bias results computed that the studies required for analysing the statistically non-significant overall effect, and there were no missing studies as per the report \[[@B44-cancers-11-00900],[@B46-cancers-11-00900],[@B102-cancers-11-00900]\].

The fact that many of the included studies did not investigate the HR values, exhibits a significant limitation in our quantitative synthesis \[[@B46-cancers-11-00900]\]. Several included studies have investigated differentially expressed miRNA as drivers of drug resistance in PC and as prognostic markers by comparing their expression level in a tumour and adjacent healthy tissue.

7. Limitations and Strengths of Our Study {#sec7-cancers-11-00900}
=========================================

High variability in the data was observed and could be the result of factors such as (1) different sample groups; (2) diverse validation methods; and (3) limited sampling. Overcoming tumour resistance remains a significant challenge in the treatment of PC. The significant factors in chemo-resistance are the presence of miRNA expressions and their genetic regulation. Our systematic review and analysis attempted to show the association between the expression levels of miRNAs and chemotherapeutic resistance in PC. This review would help achieve a better understanding of the overall network of the mechanisms contributing to drug resistance and the regulation of the correlated miRNAs.

8. Conclusions {#sec8-cancers-11-00900}
==============

This systematic review and meta-analysis of miRNA expressions identified critical determinants of chemotherapeutic sensitivity and resistance in PC and correlated these with oncogenic molecular signalling pathways. The knowledge based on the miRNA and drug targets could drive the choice of chemotherapeutic regimens used in patients, adoption of combination therapies that overcome therapeutic resistance, utilisation of miRNAs as biomarkers of chemotherapy response, and early adaptive modifications to treatment in response to alterations in miRNA profiles of tumours.

The following are available online at <https://www.mdpi.com/2072-6694/11/7/900/s1>, Table S1: The search strategy, Table S2: Quality assessment of the included studies.
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![Commonly performed in vitro assays in the included articles. ISH: in-situ Hybridization; IHC: immuno histo-chemistry; TUNEL: terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling.](cancers-11-00900-g002){#cancers-11-00900-f002}

![Hallmarks of PC. The shells highlighted in red are miRNAs that are downregulated while green denotes upregulated in pancreatic cancers in comparison to normal tissue.](cancers-11-00900-g003){#cancers-11-00900-f003}

![Forest plot for the HR and 95% CI of PC studies using meta-analysis. Random effect model; I squared = 83.833%; tau = 0.403; *Q* value = 68.042; df = 11.](cancers-11-00900-g004){#cancers-11-00900-f004}

![Forest plot of sub-group analysis for miRNA-21 of the included studies.](cancers-11-00900-g005){#cancers-11-00900-f005}

![Funnel plot of studies included in the meta-analysis.](cancers-11-00900-g006){#cancers-11-00900-f006}

![Funnel plot of studies including the imputed studies in our meta-analysis.](cancers-11-00900-g007){#cancers-11-00900-f007}

cancers-11-00900-t001_Table 1

###### 

Characteristics of 43 included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  S.No   Author                                                      Ethnicity         Period of Study                           Drug                               No. of Samples (Cancer/Normal)   Cell Culture Type                                                                                               Resistant Cells                                                                                                    miRNA                                          miRNA Profiling Platform                                                                                                                                           Pathways Associated with/Gene
  ------ ----------------------------------------------------------- ----------------- ----------------------------------------- ---------------------------------- -------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1      Yang, R. et al. (2017) \[[@B55-cancers-11-00900]\]          Chinese           2013--2016                                GEM                                157/157                          Human PC cell lines Capan-2, HPAC, SW1990, PANC-1, CFPAC-1, BXPC-3, ASPC-1, PATU-8988, HPDE6-C7 and HPNE        PANC-1-GR and BXPC-3 GR                                                                                            3656                                           Taqman microRNA Reverse Transcription kits (Thermo Fisher Scientific, Dreieich, Germany)                                                                           Ras Homolog Family Member F (RHOF)/Epithelial--mesenchymal transition (EMT)

  2      Xiao, G. et al. (2017) \[[@B56-cancers-11-00900]\]          Chinese           2015--2016                                GEM                                15/15                            HPDE6-C7, PC cell lines Panc-1 and BxPc3                                                                        NM                                                                                                                 Let-7a                                         TAKARA PrimeScript Kit                                                                                                                                             C-X-C chemokine receptor type 4 (CXCR4)/let-7a/High-mobility group AT-hook 2 (HMGA2)

  3      Hiramoto, H. et al. (2017) \[[@B57-cancers-11-00900]\]      Japanese          2000--2011                                GEM                                50                               Panc1, KP4-4, SU.86.86, BxPC3 and MDA-MB-231                                                                    NM                                                                                                                 509-5p, 1243                                   Custom Taqman miRNA Assays kit (Applied Biosystems, San Diego, CA, USA)                                                                                            E-cadherin

  4      Chaudhary, A.K. et al. (2017) \[[@B58-cancers-11-00900]\]   American          NM                                        GEM                                NM                               HPDE                                                                                                            GEM-resistant MIA PaCa-2R cells                                                                                    205-5p                                         SYBR Green-based pathway-focused miScript miRNA PCR Array (catalog number 102ZF, Qiagen, MD, USA) using Roche Light Cycler 480^®^ (Roche, Indianapolis, IN, USA)   K-ras, Caveolin-1, and Ki-67

  5      Liu. F. et al. (2017) \[[@B59-cancers-11-00900]\]           Chinese           January 2010--December 2014               GEM                                87                               BxPC-3, Panc-1, Capan-2, SW1990, Paca-2, AsPc-1, and CFPAC-1, HEK293T and HPDE                                  Capan-2, Panc-1, and AsPc-1                                                                                        153                                            SYBR Premix Ex Taq (TaKaRa, Dalian, China) and run with an Applied Biosystems ViiATM 7 Real-Time PCR System (Applied Biosystems)                                   Snail

  6      Mikamori, M. et al. (2017) \[[@B60-cancers-11-00900]\]      Japanese          March 2007--August 2015                   GEM                                45                               Panc1, MiaPaCa2, and PSN1 cell lines                                                                            Panc1-GR1, -GR3, and -GR4 cells                                                                                    155                                            TaqMan MicroRNA Assays (Applied Biosystems) and the ABI7900HT system (Applied Biosystems)                                                                          Anti-apoptotic (RAB27B)

  7      Hu, H. et al. (2016) \[[@B61-cancers-11-00900]\]            Chinese           NM                                        GEM                                15/15                            PANC-1                                                                                                          NM                                                                                                                 101                                            TaqMan microRNA assay using ABI-7300 Real-Time machine (Shanghai, China)                                                                                           DNA-dependent protein kinase catalytic subunit (DNA-PKcs)

  8      Amponsah, P. et al. (2016) \[[@B62-cancers-11-00900]\]      Deutsch           NM                                        GEM                                92/5                             ASAN-PaCa, BxPC-3, AsPC-1 and MIA-PaCa2                                                                         Bx-GEM                                                                                                             210                                            Human HT-12 v4 Expression Bead Chip Kit or the Human miR Microarray (Release 19.0)                                                                                 ABCC5

  9      Li, C. et al. (2016) \[[@B63-cancers-11-00900]\]            Chinese           2013-2015                                 GEM                                31/31                            HPDE6, PANC-1, MIAPaCa-2 and SW1990 cells                                                                       NM                                                                                                                 124                                            TaqMan microRNA assays (Applied Biosystems)                                                                                                                        miR-124/polypyrimidine tract binding protein 1 (PTBP1)/Pyruvate kinase (PKM2)

  10     Li, J. et al. (2016) \[[@B64-cancers-11-00900]\]            Chinese           NM                                        GEM                                84/20                            HPC-Y5, AsPC-1, PANC-1, BxPC-3, Hs766t and CFPAC-1                                                              NM                                                                                                                 506                                            Agilent Array                                                                                                                                                      Sphingosine kinase 1 (SPHK1)/Protein kinase B(Akt)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)

  11     Gu, J. et al. (2016) \[[@B65-cancers-11-00900]\]            Chinese           2008--2010                                GEM                                58                               PanC-1, Mia Paca-2 and HEK-293T                                                                                 NM                                                                                                                 17-5p                                          SYBR Green Mix (Roche) using All-in-One miRNA qPCR Detection Kit (GeneCopoeia, Rock, MD, USA)                                                                      Phosphatase and tensin homolog (PTEN)

  12     Tian, X. et al. (2016) \[[@B66-cancers-11-00900]\]          American          March 2009--September 2013                GEM, Lapatinib, and Capecitabine   17                               PANC-1, MIA PaCa-2 and BXCP-3 cell lines                                                                        NM                                                                                                                 7, 21, 210, 221                                RT2 miRNA first strand kit (Qiagen, Inc.) and Applied Biosystems 7900HT Fast Real-Time PCR system (Thermo Fisher Scientifc, Inc., Waltham, MA, USA)                Epidermal growth factor receptor (EGFR)1 and human epidermal growth factor receptor (HER)2 pathways

  13     Fan, P. et al. (2016) \[[@B67-cancers-11-00900]\]           Deutsch           NM                                        GEM                                21                               ASAN-PaCa, AsPC-1, PANC-1, MIA-PaCa2 and BxPC-3                                                                 Bx-GEM                                                                                                             101-3p                                         Human HT-12 v4 Expression Bead Chip Kit or the Human miR Microarray (Release 19.0).                                                                                Ribonucleotide reductase M1 (RRM1)

  14     Yao, J. et al. (2016) \[[@B68-cancers-11-00900]\]           Chinese           NM                                        GEM                                26                               SW1990 and HEK293T cells                                                                                        SW1990GZ                                                                                                           125a                                           TaqMan MicroRNA Reverse Transcription Kit (Takara), miRscript SYBR Green PCR Kit and SYBR Green PCR Kit (Takara, Dalian, China)                                    TNF Alpha-Induced Protein 3 (A20)

  15     Ren, Z. et al. (2016) \[[@B69-cancers-11-00900]\]           Chinese           NM                                        GEM                                10/10                            L3.6pl, BxPC-3, CFPAC, MiaPaCa-2, ASPC-1, PANC-1, MPanc96, HPAC, SU86.86 and HS766T                             NM                                                                                                                 203                                            mirVana RT-qPCR miRNA Detection kit (cat no. AM7659; Ambion, Austin, TX, USA)                                                                                      Salt-inducible kinase 1 (SIK1)

  16     Chen, M. et al. (2015) \[[@B70-cancers-11-00900]\]          Chinese           2008--2011                                GEM                                124/10                           PANC-1 and BXPC3                                                                                                NM                                                                                                                 181c                                           miRNA-specific TaqMan MiRNA Assay Kit (Applied Biosystems).                                                                                                        Mammalian STE20-like protein kinase 1/2 (MST1/2), and large tumour suppressor 1/2 (LATS1/2), together with the adaptor proteins Salvador homolog 1 (SAV1) and MOB kinase activator 1 (MOB1) (Hippo signalling pathway)

  17     Miyamae, M. et al. (2015) \[[@B71-cancers-11-00900]\]       Japanese          January 2010--April 2013                  GEM                                94/68                            PK-45H, PANC-1, PK-59, KP4-1, and PK-1                                                                          NM                                                                                                                 550a, 557, 575, 615-5p, 675, 744               3D-Gene miRNA microarray platform (Toray Industries, Kamakura, Japan and human TaqMan MicroRNA Assay Kit (Applied Biosystems, Foster City, CA, USA)                NM

  18     Zhang, W. et al. (2015) \[[@B72-cancers-11-00900]\]         Chinese           NM                                        GEM                                19                               HPAC, BxPC-3, Colo357, and L3.6pl                                                                               ASPC-1, Panc-1 and MiaPaCa-2                                                                                       15b, 155, 212                                  mirVana qRT-PCR miRNA detection kit (Ambion)                                                                                                                       SMAD specific E3 ubiquitin protein ligase 2 (SMURF2)

  19     Yu, C. et al. (2015) \[[@B73-cancers-11-00900]\]            Chinese           2013--2014                                5-FU                               18                               AsPC-1, BxPc-3, Capan-1, Capan-2, CFPAC-1, PANC-1, MIA PaCa-2 & SW1990                                          NM                                                                                                                 138-5p                                         Fluorescence-activated cell sorting (FACSnCanto II flow cytometer; BD Biosciences, San Jose, CA, USA)                                                              Vimentin (VIM)

  20     Liang, C. et al. (2015) \[[@B74-cancers-11-00900]\]         Chinese           2010--2012                                GEM                                106                              PCI35 & PCI55, SW1990, MiaPaca-2, PANC-1, BxPC-3, Capan-1                                                       NM                                                                                                                 33a                                            NM                                                                                                                                                                 AKT/Gsk-3β/β-catenin pathway

  21     Liu, Y. et al. (2015) \[[@B75-cancers-11-00900]\]           Chinese           2007--2010                                5-FU, GEM                          86/41                            AsPC-1, BXPC-3, SW1990, MIAPaCa-2, PANC-1 & HPDE                                                                NM                                                                                                                 494                                            NM                                                                                                                                                                 miR-494/c-Myc/SIRT1 pathway

  22     Meidhof, S. et al. (2015) \[[@B76-cancers-11-00900]\]       Deutsch           NM                                        GEM                                27/27                            Panc-1, MDA-MB-231, BxPC3, H358, DU-145, hPaca-1 and hPaca-2                                                    BxPC3 GEM-resistant cells, Tarceva-resistant H358 cells                                                            203                                            Roche LightCycler 480                                                                                                                                              ZEB-1

  23     Zhao, Y. et al. (2015) \[[@B77-cancers-11-00900]\]          Deutsch           NM                                        GEM                                28/28                            L3.6pl                                                                                                          L3.6pl - GemR                                                                                                      21,221                                         miScript SYBR^®^ Green PCR Kit (Qiagen, USA)                                                                                                                       NM

  24     Li, Z. et al. (2014) \[[@B78-cancers-11-00900]\]            Chinese           2013-2014                                 GEM                                23/23                            AsPC1, BxPc-3, Capan-1, Capan-2, CFPAC-1, PANC-1, MIA PaCa-2, SW1990                                            NM                                                                                                                 100                                            TaqMan miRNA Assay (Applied Biosystems)                                                                                                                            FGFR3

  25     Xu, J. et al. (2014) \[[@B79-cancers-11-00900]\]            Chinese           NM                                        GEM                                87                               SW1990, MiaPaCa-2                                                                                               SW1990/GEM                                                                                                         497                                            NM                                                                                                                                                                 FGF/FGFR signalling pathway

  26     Hasegawa, S. et al. (2014) \[[@B80-cancers-11-00900]\]      Japanese          2007-2010                                 5-FU, GEM                          24                               Panc1-P, Panc1-GR                                                                                               Panc-1GemR                                                                                                         1246                                           Comparative CT method                                                                                                                                              CCNG2

  27     Lai, I.-L. et al. (2014) \[[@B81-cancers-11-00900]\]        Americans         NM                                        GEM                                NM                               Panc-1, AsPC-1 and BxPC-3                                                                                       Panc-1GemR, BxPC3GemR and AsPC-1GemR                                                                               520f                                           Bio-Rad CFX Manager 2.1 detection system and miScript PCR starter kit (Qiagen)                                                                                     ATM/ATR checkpoint pathway

  28     Song, W.-F. et al. (2013) \[[@B82-cancers-11-00900]\]       Chinese           2010--2012                                GEM                                41                               BxPc3, HPAF, HPAC, Capan, PANC-1 and PL-45 cell lines                                                           HPAC and PANC-1/GEM                                                                                                21                                             Specific Taqman MicroRNA assays (Applied Biosystems)                                                                                                               PTEN/Akt pathway

  29     Peng, F. et al. (2013) \[[@B83-cancers-11-00900]\]          Chinese           2010--2011                                5-FU                               14                               TFK-1, QBC939 cell line                                                                                         NM                                                                                                                 220b, 200c and 429                             mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA), Agilent Human miRNA Microarray Kit (V2) (Agilent Inc, Santa Clara, CA, USA) for analysis.                   SUZ12, ROCK2 direct targets

  30     Nagano, H. et al. (2013) \[[@B84-cancers-11-00900]\]        Japanese          September 1999--February 2004             GEM                                18                               MIAPaCa-2, PSN-1, BxPC-3, Panc-1                                                                                NM                                                                                                                 29a                                            TRIzol agent (Invitrogen, Carlsbad, CA, USA)                                                                                                                       Wnt/β-catenin signaling pathway

  31     Wei, F. et al. (2013) \[[@B85-cancers-11-00900]\]           Chinese           NM                                        Radiation and AZD8055              NM                               PANC-1, Capan-2, BxPC-3                                                                                         NM                                                                                                                 99b                                            NM                                                                                                                                                                 mTOR

  32     Iwagami, Y. et al. (2013) \[[@B86-cancers-11-00900]\]       Japanese          1992--2008                                GEM                                66                               MiaPaCa2 and PSN1                                                                                               MiaPaCa2-RGs, PSN1-RGs                                                                                             320c                                           NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA                                                                                     SMARCC1 mediated anti-cancer effect of GEM

  33     Bhutia, Y.D. et al. (2013) \[[@B87-cancers-11-00900]\]      Americans         NM                                        GEM                                10/2                             MIA PaCa-2                                                                                                      L3.6pl and Capan-1/GEM                                                                                             let-7a                                         miRNA Isolation Kit and the TaqManH MicroRNA Reverse Transcription Kit (Applied Biosystems)                                                                        RRM2

  34     Wang, P. et al. (2012) \[[@B88-cancers-11-00900]\]          Chinese           Cohort1: 2003--2005 Cohort2: 2009--2010   GEM                                NM                               Panc-1, BxPC3                                                                                                   NM                                                                                                                 21                                             RecoverAll Total Nucleic Acid Isolation Kit (Ambion)                                                                                                               FasL/Fas pathway

  35     Singh, S. et al. (2013) \[[@B89-cancers-11-00900]\]         NM                NM                                        GEM                                NM                               MIA PaCa-2                                                                                                      MI PaCa-2/GEM                                                                                                      7, 146, 205                                    SYBR Green dye universal master mix on a Light Cycler 480 (Roche, Indianapolis)                                                                                    Class III b-tubulin (TUBB3)

  36     Brabletz, S. et al. (2011) \[[@B90-cancers-11-00900]\]      NM                NM                                        GSI                                NM                               Panc1, HPAF2, MCF7, MiaPaCa2                                                                                    NM                                                                                                                 200                                            Pfu Ultra Hotstart 2 Master Mix (Stratagene, Santa Clara)                                                                                                          Notch signaling

  37     Ali, S. et al. (2010) \[[@B91-cancers-11-00900]\]           NM                NM                                        GEM, OHP, tarceva                  50/10                            MIAPaCa-2, AsPc-1                                                                                               MIAPaCa-GR (GEM resistant), AsPc-1OR (oxaliplatin resistant), MIAPaCa-GTR, AsPc-1GTR (GEM and tarceva resistant)   21, 146a, 200b, 200c, 221, let-7b and let-7d   TaqMan MicroRNA Assay kit (Applied Biosystems)                                                                                                                     NM

  38     Hwang, J.-H. et al. (2010) \[[@B92-cancers-11-00900]\]      Korean, Italian   1999--2007 and 2001--2004                 GEM, 5-FU                          127                              BxPc3, HPAF-II, HPAC, PANC1, PL45                                                                               NM                                                                                                                 21                                             TaqMan-microRNA assays and the 7900 HT-Fast RealTime PCR (Applied Biosystems, Foster City, CA, USA)                                                                NM

  39     Giovannetti, E. et al. (2010) \[[@B93-cancers-11-00900]\]   Deutsch           2001--2004                                GEM                                81                               hTERT-HPNE, Hhs27, LPc006, LPc033, LPc067, LPc111, LPc167, PP437                                                NM                                                                                                                 21                                             7500HT sequence detection system (Applied Biosystems)                                                                                                              PTEN and PI3K-Akt pathway

  40     Moriyama, T. et al. (2009) \[[@B94-cancers-11-00900]\]      Japanese          2000--2008                                GEM                                25/25                            AsPC-1, KP-1N, KP-2, KP-3, PANC-1, SUIT-2 MIA PaCa-2, CAPAN-1, CAPAN-2, CFPAC-1, H48N, HS766T, SW1990, NOR-P1   NM                                                                                                                 21                                             mirVana qRT-PCR miRNA Detection Kit, and mirVana Primer Sets (all from Ambion)                                                                                     VEGF and MMP-2 and MMP-9

  41     Xiong G et al. (2018) \[[@B95-cancers-11-00900]\]           Chinese           NM                                        GEM                                90/90                            AsPC-1, BxPC-3, MiaPaCa-2, PANC-1, Su86. 86, T3M4                                                               AsPC-1-Gem                                                                                                         10a-5p                                         Genepharma (Shanghai, China)                                                                                                                                       TFPA2C

  42     Sun, D. et al. (2018)                                       Chinese           January 2007--December 2015               GEM                                87/8                             BxPC-3, PANC-1, AsPC-1, SW1990, Capan-1, Capan-2, CFPAC-1 and MIA PaCa-2                                        NM                                                                                                                 374b-5p                                        LightCycler^®^ 480\                                                                                                                                                BIAPRC-3 and XIAP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       SYBR-Green I Master (Roche Diagnostics, Basel, Switzerland).                                                                                                       

  43     You, L. et al. (2018)                                       Chinese           NM                                        GEM                                10                               293T, MIA\                                                                                                      GEM-R cells BxPC-3 and PANC-1                                                                                      1207                                           (Bio-Rad, Hercules, CA, USA)                                                                                                                                       PVT1
                                                                                                                                                                                                     PaCa-2, Su.86.86, Capan-1, PANC-1, SW1990, BxPC-3 and AsPC-1                                                                                                                                                                                                                                                                                                                                                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NM-Not Mentioned.

cancers-11-00900-t002_Table 2

###### 

miRNAs that are involved in chemoresistance and pathways that are modulated.

  Chemoresistance                                            
  ----------------- ----------------------------- ---------- --------------------------------------------------------------------------------------------------
  **GEM**                                         **GEM**    
  210               ABCC5                         17-5p      PTEN
  124               PTBP1/PKM2                    221        EGFR and HER pathways
  101-3p            RRM1                          203        SIK1
  100               FGFR3                         181c       MST1/2, and LATS1/2, together with the adaptor proteins SAV1 and MOB1 (Hippo signalling pathway)
  497               FGF/FGFR signalling pathway   15b        SMURF2
  7                 TUBB3                         21         NM
  205               TUBB3                         221        NM
  374b-5p           BIAPRC-3 and XIAP             1246       CCNG2
  **5-FU**                                        21         PTEN/Akt pathway
  200c              SUZ12, ROCK2 direct targets   320c       SMARCC1 mediated the anti-cancer effect of GEM
  220b              SUZ12, ROCK2 direct targets   155        Anti-apoptotic (RAB27B)
                                                  21         NM
                                                  221        NM
                                                  21         VEGF and MMP-2 and MMP-9
                                                  10a-5p     TFAP2C
                                                  **5-FU**   
                                                  1246       CCNG2

cancers-11-00900-t003_Table 3

###### 

miRNAs that are involved in chemosensitivity and pathways that are modulated.

  Chemosensitivity                                            
  ------------------ ----------------------------- ---------- ------------------------------
  **GEM**                                          **GEM**    
  3656               RHOF/EMT                      509-5p     E-cadherin
  Let-7a             CXCR4/HMGA2                   1243       E-cadherin
  205-5p             K-ras, Caveolin-1 and Ki-67   33a        AKT/Gsk-3β/β-catenin pathway
  153                SNAIL                         21         FasL/Fas pathway
  101                DNA-PKcs                      1207       PVT1
  506                SPHK1/Akt/NF-κB               **5-FU**   
  494                c-Myc/SIRT1 pathway           138-5p     vimentin
  203                ZEB-1                                    
  **5-FU**                                                    
  494                c-Myc/SIRT1 pathway                      

cancers-11-00900-t004_Table 4

###### 

Publication bias of the included studies.

  --------------- ------------------------ ------------------------- ----------------------- ----------------------- ------------------------ --------------------------------------- -------------------------- --------------- --------------- -------- -------------- --------------- -------------- --------------- ---
  **Groups**      **Clinical Outcomes**    **Classic Fail-Safe N**   **Orwin Fail-Safe N**   **Begg and Mazumdar**   **Egger′s Regression**   **Dual and Tweedie (Random Effects)**                                                                                                                                     
                                           ***z*-Value**             ***p*-Value**           **HR in Observed**      **Tau**                  ***z*-Value**                           ***p*-Value**              **Intercept**   ***p*-Value**   **df**   **Observed**   ***q*-Value**   **Adjusted**   ***q*-Value**   
  **Main**        **Main Meta-analysis**   6.264                     0                       1.150                   0.257                    1.165                                   0.243                      1.778           0.052           10       1.603          68.041          1.132          107.980         
                                                                                             **Fixed**               **Mixed/Random**         **Hypothesis Test**                                                                                                                                                       
  **Subgroups**   **Heterogeneity**        **HR**                    **95% CI**              **HR**                  **95% CI**               **Fixed effects model**                 **Random effects model**                                                                                                          
  **Q**           **P**                    **I^2^**                  **Low**                 **High**                **Low**                  **High**                                **Z**                      **P**           **Studies**     **Z**    **P**          **Studies**                                    
  miR-21          1.683                    0.195                     40.567                  1.913                   1.340                    2.732                                   2.061                      1.195           3.556           3.569    0              2               2.599          0.009           2
  --------------- ------------------------ ------------------------- ----------------------- ----------------------- ------------------------ --------------------------------------- -------------------------- --------------- --------------- -------- -------------- --------------- -------------- --------------- ---
